Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lingying Huang

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
BMJ Open|September 14, 2024
Investigating the efficacy of acupuncture in treating patients with metabolic-associated fatty liver disease: a protocol for a randomised controlled clinical trialLihong Fu, Lingying Huang, Yueqiu Gao, et al.
Journal of Ethnopharmacology|April 15, 2024
Ba-Qi-Rougan formula alleviates hepatic fibrosis by suppressing hepatic stellate cell activation via the MSMP/CCR2/PI3K pathwayYan Xue, Wanchun Zhu, Fengjie Qiao, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|February 10, 2024
Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/β-catenin signalingXuemei Zhang, Xiaona Lu, Jia Shi, et al.
Medicine|December 23, 2025
ABCB1 rs2032582 variant is potentially linked withScutellariae Radix-induced liver injury: A case reportYiwen Tang, Lihong Fu, Xinrui Ren, et al.
Heliyon|November 30, 2023
Integrating bulk and single-cell RNA sequencing data to establish necroptosis-related lncRNA risk model and analyze the immune microenvironment in hepatocellular carcinomaRongjie Zhang, Qian Li, Xiaoxiao Yu, et al.
Scientific Reports|March 3, 2018
Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinaseZhuo Yu, Hai Feng, Xuehua Sun, et al.
Ebiomedicine|August 29, 2018
Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signalingHaibin Song, Zhuo Yu, Xuehua Sun, et al.
Cellular Oncology (Dordrecht, Netherlands)|July 6, 2020
Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradationZhuo Yu, Hai Feng, Yunhui Zhuo, et al.
Journal of Ethnopharmacology|October 19, 2025
The mechanisms and therapeutic potential of Atractylodes macrocephala Koidz in chronic liver disease managementJunhua Feng, Xue Wang, Longshan Ji, et al.
Journal of Proteomics|July 7, 2025
Potential use of serum microvesicle indicators to distinguish different types of drug-induced liver injuryLihong Fu, Liwen Zhang, Guangyuan Huo, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
BMJ Open|September 14, 2024
Investigating the efficacy of acupuncture in treating patients with metabolic-associated fatty liver disease: a protocol for a randomised controlled clinical trialLihong Fu, Lingying Huang, Yueqiu Gao, et al.
Journal of Ethnopharmacology|April 15, 2024
Ba-Qi-Rougan formula alleviates hepatic fibrosis by suppressing hepatic stellate cell activation via the MSMP/CCR2/PI3K pathwayYan Xue, Wanchun Zhu, Fengjie Qiao, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|February 10, 2024
Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/β-catenin signalingXuemei Zhang, Xiaona Lu, Jia Shi, et al.
Medicine|December 23, 2025
ABCB1 rs2032582 variant is potentially linked withScutellariae Radix-induced liver injury: A case reportYiwen Tang, Lihong Fu, Xinrui Ren, et al.
Heliyon|November 30, 2023
Integrating bulk and single-cell RNA sequencing data to establish necroptosis-related lncRNA risk model and analyze the immune microenvironment in hepatocellular carcinomaRongjie Zhang, Qian Li, Xiaoxiao Yu, et al.
Scientific Reports|March 3, 2018
Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinaseZhuo Yu, Hai Feng, Xuehua Sun, et al.
Ebiomedicine|August 29, 2018
Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signalingHaibin Song, Zhuo Yu, Xuehua Sun, et al.
Cellular Oncology (Dordrecht, Netherlands)|July 6, 2020
Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradationZhuo Yu, Hai Feng, Yunhui Zhuo, et al.
Journal of Ethnopharmacology|October 19, 2025
The mechanisms and therapeutic potential of Atractylodes macrocephala Koidz in chronic liver disease managementJunhua Feng, Xue Wang, Longshan Ji, et al.
Journal of Proteomics|July 7, 2025
Potential use of serum microvesicle indicators to distinguish different types of drug-induced liver injuryLihong Fu, Liwen Zhang, Guangyuan Huo, et al.
Pageof 2